Actinogen Medical - On track to start Phase IIb XanaMIA study
Actinogen’s recent quarterly update confirmed that the company remains on track to start US recruitment in H1 CY23 for its six-month,...
228 Views
Actinogen Medical - XanaMIA clears hurdle to start US recruitment
Actinogen has announced that the US FDA has provided the required approvals for it to proceed with US recruitment for its planned six-month,...
671 Views
Actinogen Medical - XanaCIDD study in MDD now underway
Actinogen announced that the first patient was randomised and treated in its XanaCIDD Phase II study in major depressive disorder (MDD) assessing...
672 Views
Actinogen Medical - Cognitive enhancer targeting key diseases
Actinogen Medical is developing its lead asset, small molecule Xanamem, a selective 11β-HSD1 inhibitor designed to cross the blood-brain barrier...
662 Views
Actinogen Medical - Cognitive enhancer targeting key diseases
Actinogen’s share price has experienced a rather volatile period since May 2019, when it decreased c 70% following the disappointing Phase II...
672 Views